For example, whole-exome sequencing before and after chemoradiotherapy showed that co-occurring KRAS/TP53 mutations in rectal cancers conferred a poor response, confirming the radioresistance associated with this genotype (116, 176, 177). Here, KRAS is linked to rectal cancer.